Stanford University researchers develop non-invasive urine test to predict bladder cancer recurrence and personalize immunotherapy

Stanford researchers develop a urine-based liquid biopsy that identifies residual bladder cancer DNA, allowing for personalized immunotherapy decisions.

By: AXL Media

Published: Apr 8, 2026, 11:15 AM EDT

Source: Information for this report was sourced from Stanford Medicine

Liquid Biopsy Innovation Challenges Conventional Diagnostic Limitations

A research team at Stanford Medicine has developed a highly sensitive urine-based liquid biopsy designed to identify minimal residual disease in patients with non-muscle invasive bladder cancer. According to a study published in the journal Cell, the test tracks fragments of tumor DNA to determine if microscopic traces of cancer remain after initial surgical removal. This molecular approach addresses a significant gap in current oncology, as clinicians previously lacked reliable tools to confirm whether a patient was fully cleared of disease or required aggressive secondary treatment.

Biological Background Interference Resolved Through Statistical Modeling

The development of the test required overcoming a complex biological hurdle known as clonal cystopoiesis, where healthy bladder lining develops mutations as a natural part of the aging process. According to William Shi, a lead author of the study, these non-cancerous genetic alterations often mimic the signals of active malignancy, which has historically compromised the accuracy of sensitive diagnostic tests. To solve this, the Stanford investigators created a specialized statistical framework that successfully isolates true cancerous DNA from the benign background mutations found in the urothelium.

Strategic Categorization of Patient Response Profiles

By monitoring patients across different stages of care, the researchers identified three distinct molecular response patterns that dictate the necessity of follow-up care. Some individuals are classified as surgery responders, meaning their tumor DNA disappears immediately after the initial procedure, while others are identified as BCG responders who require immunotherapy to clear remaining DNA. A third group, classified as non-responders, shows persistent or increasing tumor DNA despite receiving standard treatments. Joseph Liao, a co-senior author, noted that this breakthrough marks the first time medical professionals can clearly separate those cured by surgery from those specifically benefiting from immunotherapy.